A Phase 3 Study in India to Describe the Safety and Immunogenicity of RSVpreF
A PHASE 3 STUDY IN INDIA TO DESCRIBE THE SAFETY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS (RSV) PREFUSION F SUBUNIT VACCINE IN ADULTS
The purpose of this phase 3 multicenter, double-blinded, placebo-controlled study in India is to learn about the safety and immunogenicity of RSVpreF in adults.
研究概览
研究类型
注册 (估计的)
阶段
- 第三阶段
联系人和位置
学习联系方式
- 姓名:Pfizer CT.gov Call Center
- 电话号码:1-800-718-1021
- 邮箱:ClinicalTrials.gov_Inquiries@pfizer.com
学习地点
-
-
Andhra Pradesh
-
Visakhapatnam、Andhra Pradesh、印度、530002
- 招聘中
- King George Hospital
-
-
Karnataka
-
Bangalore、Karnataka、印度、560060
- 招聘中
- BGS Global Institute of Medical Sciences (BGSGIMS)
-
Bangalore、Karnataka、印度、560085
- 招聘中
- Radhakrishna Multispeciality Hospital and IVF Center
-
Belagavi、Karnataka、印度、590001
- 招聘中
- Belagavi Institute of Medical Sciences - Belagavi
-
-
Maharashtra
-
Nashik、Maharashtra、印度、422003
- 招聘中
- Suyog Hospital
-
Pune、Maharashtra、印度、411043
- 招聘中
- Bharati Vidyapeeth {Deemed to be University) Medical College Hospital & Research Centre
-
-
National Capital Territory of Delhi
-
Dwarka、National Capital Territory of Delhi、印度、110075
- 招聘中
- Aakash Healthcare Private Limited
-
New Delhi、National Capital Territory of Delhi、印度、110060
- 招聘中
- Sir Ganga Ram Hospital
-
New Delhi、National Capital Territory of Delhi、印度、110029
- 招聘中
- All India Institute Of Medical Sciences
-
-
Rajasthan
-
Jaipur、Rajasthan、印度、302039
- 招聘中
- Maharaja Agrasen Superspeciality Hospital
-
-
Tamil Nadu
-
Chengalpattu、Tamil Nadu、印度、603203
- 招聘中
- SRM Medical College Hospital and Research Centre - Kattankulathur
-
Kelambākkam、Tamil Nadu、印度、603103
- 招聘中
- Chettinad Hospital and Research Institute
-
-
West Bengal
-
Kolkata、West Bengal、印度、700020
- 招聘中
- Institute of Post Graduate Medical Education & Research, SSKM Hospital
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Key Inclusion Criteria:
- Participants ≥18 years of age at Visit 1.
- Participants who are ambulatory and live independently in the community.
- Participants who are determined by medical history, physical examination (if required), and clinical judgment of the investigator to be eligible for inclusion in the study.
- Applicable to participants 18 through 59 years of age: Participants who are healthy or have stable preexisting diseases. These participants are considered at high risk of RSV disease by having at least 1 reportable stable chronic medical condition(s) that belongs to 1 or more of the following:
- Chronic heart disease (ie, coronary artery disease, heart failure, or congenital heart disease)
- Chronic lung disease (ie, COPD, emphysema, asthma, interstitial lung disease, or cystic fibrosis)
- Nongestational diabetes mellitus type 1 or type 2
- Severe obesity (body mass index [BMI] ≥40 kg/m2)
- Chronic liver disease (ie, cirrhosis)
- Chronic kidney disease (not including end-stage renal disease with or without dialysis)
- Chronic neurological disease that causes impaired airway clearance or respiratory muscle weakness (ie, poststroke dysphagia, amyotrophic lateral sclerosis, or muscular dystrophy)
- Chronic hematologic disease (ie, sickle cell disease or thalassemia)
Note: A chronic medical condition for this study is defined as:
- Duration ≥6 months.
- Requires regular medical follow-up or ongoing prescribed medication or hospitalization in the previous year.
- Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent document (ICD) and in the protocol.
Key Exclusion Criteria:
- Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection.
- History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention(s) or any related vaccine.
- Prior history of any subtype of Guillain-Barré syndrome of any etiology.
- Serious chronic disorder, including metastatic malignancy, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the participant from participating in the study.
- Immunocompromised individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination.
- Individuals who receive chronic systemic treatment with immunosuppressive therapy, including cytotoxic agents, immunosuppressive monoclonal antibodies, systemic corticosteroids, or radiotherapy, eg, for cancer or an autoimmune disease, from 60 days before study intervention administration or planned receipt throughout the study.
学习计划
研究是如何设计的?
设计细节
- 主要用途:预防
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:双倍的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
安慰剂比较:Placebo
Placebo |
Placebo |
|
实验性的:RSVpreF
RSVpreF Vaccine |
RSVpreF Vaccine |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Neutralizing Titers (NTs) for RSV A and RSV B expressed as Geometric Mean Titers (GMT)
大体时间:Before vaccination, 1 month after vaccination
|
Before vaccination, 1 month after vaccination
|
|
|
NTs for RSV A and RSV B expressed as Geometric Mean Fold Rise (GMFR)
大体时间:Before vaccination, 1 month after vaccination
|
Before vaccination, 1 month after vaccination
|
|
|
NTs for RSV A and RSV B expressed as seroresponse rate
大体时间:1 month after vaccination
|
1 month after vaccination
|
|
|
Proportion of participants reporting local reactions within 7 days following investigational product administration
大体时间:Within 7 days
|
Describe local reactions following investigational product administration |
Within 7 days
|
|
Percentage of participants reporting systemic events within 7 days following investigational product administration
大体时间:Within 7 days
|
Describe systemic events following investigational product administration |
Within 7 days
|
|
Percentage of participants reporting adverse events (AEs) through 1 month following investigational product administration
大体时间:1 month after vaccination
|
Describe AEs occurring through 1 month following administration of investigational product |
1 month after vaccination
|
|
Percentage of participants reporting serious adverse events (SAEs) throughout the study
大体时间:3 months after vaccination
|
Describe SAEs through 3 months following administration of investigational product |
3 months after vaccination
|
合作者和调查者
赞助
调查人员
- 研究主任:Pfizer CT.gov Call Center、Pfizer
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
关键字
其他研究编号
- C3671040
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
在美国制造并从美国出口的产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.